American journal of translational research最新文献

{"title":"Endostar and chemoradiotherapy for advanced cervical cancer: comparing efficacy and prognosis.","authors":"Juan Liao, Jie Li, Tong Hu, Yan Nan","doi":"10.62347/PJVO5304","DOIUrl":"https://doi.org/10.62347/PJVO5304","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy of endostar combined with simultaneous chemoradiotherapy versus conventional treatment methods for locally advanced cervical cancer (LACC) and assess the prognosis of these patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the medical records of 182 LACC patients treated at Shaanxi Provincial Cancer Hospital between January 2017 and February 2021. Of these, 88 patients underwent conventional synchronous chemoradiotherapy (control group), while 94 patients received endostar combined with synchronous chemoradiotherapy (combined group). Treatment efficacy, adverse reactions, and tumor marker levels before and after treatment were compared. The 1-year and 3-year survival rates of the two groups were analyzed. Risk factors for 3-year mortality were identified through Cox regression analysis, and the prognostic predictive value of independent factors was assessed using ROC curve analysis.</p><p><strong>Results: </strong>The objective remission rate (ORR) in the combined group (74.47%) was significantly higher than that in the control group (54.55%, <i>P</i><0.005). Adverse reactions, including gastrointestinal symptoms, bone marrow suppression, liver and kidney function abnormalities, and skin damage, showed no significant differences between the groups (<i>P</i>>0.05). Post-treatment levels of squamous cell carcinoma antigen (SCC-Ag), carbohydrate antigen 125 (CA125), and carcinoembryonic antigen (CEA) were significantly lower in the combined group (<i>P</i><0.05). The 1-year and 3-year survival rates were notably higher in the combined group (<i>P</i><0.05). Cox regression analysis identified FIGO stage, histologic grade, and post-treatment SCC-Ag levels as independent risk factors for 3-year mortality, while endostar combined with chemoradiotherapy was an independent protective factor. ROC curve analysis demonstrated AUC values of 0.614 (FIGO stage), 0.625 (histologic grade), 0.622 (treatment modality), and 0.662 (post-treatment SCC-Ag).</p><p><strong>Conclusion: </strong>Endostar combined with synchronous chemoradiotherapy for LACC significantly improves short-term treatment efficacy and long-term survival outcomes compared to chemoradiotherapy alone. This approach is safe and does not increase adverse effects, highlighting its potential as a superior treatment strategy.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1388-1401"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of <i>Picrasma quassioides</i> against hepatocellular carcinoma elucidated by network pharmacology and experimental validation.","authors":"Jie Zhou, Zhilan Zhang, Ruiru Huang, Xingxing Zhuang, Shoudong Ni","doi":"10.62347/VLGD3371","DOIUrl":"https://doi.org/10.62347/VLGD3371","url":null,"abstract":"<p><strong>Objective: </strong>The medicinal plant <i>Picrasma quassioides</i> (<i>P. quassioides</i>) Benn exerts an inhibitory effect on the growth of hepatocellular carcinoma (HCC) cells via an unknown mechanism. This study explored the targets and signaling pathways underlying the mechanism of <i>P. quassioides</i> against HCC.</p><p><strong>Methods: </strong>Targets of <i>P. quassioides</i> active compounds were identified using the HERB database, and the HCC targets were found with the GeneCards database. The optimal serum concentration and intervention time were determined using the CCK-8 assay. Apoptosis, cell cycle, invasion, cloning, and wound-healing abilities were assessed using flow cytometry. Core protein targets and signaling pathway-related metabolic enzymes were evaluated with Western blotting. The anti-HCC effect of <i>P. quassioides</i> medicated serum was verified using arachidonic acid (AA)-related enzyme agonists.</p><p><strong>Results: </strong>Network pharmacology identified 19 effective compounds of <i>P. quassioides</i> and 105 HCC-associated targets. It also revealed the AA pathway was the central pathway of <i>P. quassioides</i> against HCC, with <i>AURKA</i>, <i>AURKB</i>, <i>KIF11</i>, and <i>TOP2A</i> identified as core targets that inhibit excessive HCC cell proliferation and promote apoptosis. Flow cytometry findings supported that <i>P. quassioides</i> medicated serum significantly inhibited HCC cell proliferation and promoted apoptosis. By contrast, enzyme agonists related to the AA pathway markedly counteracted the anti-HCC effect of <i>P. quassioides</i>, promoting HCC growth.</p><p><strong>Conclusion: </strong><i>P. quassioides</i> medicated serum exerts a prominent anti-HCC effect in vitro. The AA pathway constitutes the mechanism by which <i>P. quassioides</i> medicated serum inhibits excessive proliferation and promotes apoptosis of HCC cells.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1402-1415"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiR-145-5p inhibits proliferation of hepatocellular carcinoma, acting through PAI-1.","authors":"Jin Li, Jianfang Ma","doi":"10.62347/NPLT8946","DOIUrl":"https://doi.org/10.62347/NPLT8946","url":null,"abstract":"<p><strong>Objectives: </strong>Hepatocellular carcinoma (HCC) mostly developsfrom cirrhosis, so we compared the miRNA profiles of patients with cirrhosis who developed HCC with those who did not, and screened for miR-145-5p, which may be involved in the progression of liver cancer. The study's purpose was to explore the mechanism of miR-145-5p in cirrhosis that becomes HCC.</p><p><strong>Methods: </strong>Cell counting kit 8 (CCK-8) and clone formation assays were employed to calculate cell proliferative ability. Quantitative real-time PCR (qRT-PCR) was conducted to measure the mRNA levels of miR-145-5p, plasminogen activator inhibitor 1 (PAI-1), and Circular RNA PVT1 (circPTV1).</p><p><strong>Results: </strong>MiR-145-5p was downregulated in HCC, and miR-145-5p inhibited Huh-7 cell viability and clone formation. The Area Under the Curve (AUC) of miR-145-5p for distinguishing between the HCC and Tumor-free groups was 0.900, indicating a high diagnostic accuracy. PAI-1 was identified as a downstream target of miR-145-5p. Silencing PAI-1 decreased the viability and clone formation of Huh-7 cells. circPVT1 directly binding to miR-145-5p in HuH-7 cells. circPVT1 regulates cell viability and clone formation through miR-145-5p. In summary, we identified miRNA miR-145-5p, which was lowly expressed in HCC, and inhibited the viability and clone formation of HCC cells.</p><p><strong>Conclusion: </strong>Our research elucidates the regulatory role of the circPVT1/miR-145-5p/PAI-1 axis in HCC, suggesting its potential as a novel diagnostic biomarker or therapeutic target for HCC.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"888-896"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of remimazolam tosylate on the response to endotracheal intubation under general anesthesia in patients undergoing catheter placement for peritoneal dialysis.","authors":"Jing Zong, Peihua Yuan, Ruijiao Zhang, Shiyin Wu, Mei Liu, Liangchao Qu","doi":"10.62347/XWSD5681","DOIUrl":"https://doi.org/10.62347/XWSD5681","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to observe the effects of remimazolam tosylate on the response to endotracheal intubation under general anesthesia in patients undergoing peritoneal dialysis catheter placement. Additionally, we seek to determine the 95% effective dose (ED95) of remimazolam tosylate for inhibiting the endotracheal intubation response in this patient population.</p><p><strong>Methods: </strong>This prospective study was registered with the China Clinical Trials Center (ChiCTR2200055709), https://www.chictr.org.cn/showproj.html?proj=149640. Patients scheduled for peritoneal dialysis catheter placement under general anesthesia at the First Affiliated Hospital of Nanchang University between January and June 2023 were selected. They were randomly assigned into the remimazolam tosylate group (R group) and the propofol group (P group), with 30 patients in each group. After anesthesia induction and subsequent endotracheal intubation, sedation efficacy and adverse reactions were recorded for both groups. Venous blood samples (1 mL) were collected from patients before anesthesia induction and after endotracheal intubation to measure levels of adrenaline and noradrenaline. The modified Dixon sequential method was used to determine the ED95 of remimazolam tosylate for inhibiting the endotracheal intubation response.</p><p><strong>Results: </strong>Levels of adrenaline and noradrenaline decreased significantly after endotracheal intubation in both the R group and P group, with no significant difference. Vital signs were more stable in the R group compared to the P group. Injection pain during anesthesia induction was reported in 3 patients (10%) in the R group, whereas 18 cases (60%) were observed in the P group. The Dixon sequential experiment included a total of 25 patients, with 13 (52%) showing positive responses and 12 (48%) negative responses.</p><p><strong>Conclusions: </strong>Remimazolam tosylate is effective for inhibiting the systemic response to endotracheal intubation in patients undergoing peritoneal dialysis catheter placement. Additionally, the occurrence rate of hypotension and injection pain during anesthesia induction is significantly lower compared to propofol. The ED95 of remimazolam tosylate for inhibiting the endotracheal intubation response in peritoneal dialysis catheter placement patients is 0.332 mg/kg.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"974-982"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CXCL14 regulates ovarian endometriosis progression by targeting PCNA.","authors":"Meng Liu, Yan Zhang, Yayun Zhang, Ting Fu, Xiaoxue Xi, Shunyu Hou","doi":"10.62347/VXNW1213","DOIUrl":"https://doi.org/10.62347/VXNW1213","url":null,"abstract":"<p><strong>Objective: </strong>To explore the regulatory function and mechanism of CXCL14 in endometriosis.</p><p><strong>Methods: </strong>Quantitative real-time polymerase chain reaction (qRT-PCR) was used to examine the expression of CXCL14 in eutopic and ectopic endometrial stromal cells (ESCs) derived from patients with endometriosis and in situ endometrial stromal cells derived from healthy individuals. Alterations in cell proliferation and migration capabilities were assessed through Cell Counting Kit-8 (CCK8) and transwell assays following the silencing or overexpression of CXCL14. Mass spectrometry was employed to identify potential interacting proteins of CXCL14, and proliferating cell nuclear antigen (PCNA) was selected for further investigation. The regulatory mechanism of PCNA by CXCL14 was further examined using co-immunoprecipitation (co-IP), Western blotting, and cellular experiments.</p><p><strong>Results: </strong>CXCL14 was highly expressed in ovarian endometriosis. The proliferative and migratory abilities of ESCs were positively correlated with CXCL14 expression levels. Moreover, CXCL14 interacted with PCNA. Silencing CXCL14 expression increased PCNA ubiquitination and promoted its degradation. Conversely, overexpression of PCNA mitigated the inhibitory effects of CXCL14 silencing on ESCs.</p><p><strong>Conclusions: </strong>CXCL14 may regulate PCNA through the ubiquitination pathway, thereby promoting the development and progression of endometrial stromal cells. This study provides new insights into the pathogenesis of endometriosis, highlighting the potential of CXCL14 as a therapeutic target.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1251-1264"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors affecting chemotherapy response after the first relapse of B-cell acute lymphoblastic leukemia in pediatric patients.","authors":"Shu-Wan Dong, Hong Zhang, Jing Wang, Shi-Yong Huang, Hui-Cai Wang","doi":"10.62347/YDNO1939","DOIUrl":"https://doi.org/10.62347/YDNO1939","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the factors affecting chemotherapy efficacy following first relapse in pediatric B-cell acute lymphoblastic leukemia (B-ALL).</p><p><strong>Methods: </strong>A retrospective investigation was conducted on the clinical data from 254 pediatric patients with B-ALL treated at the First Affiliated Hospital of Xinjiang Medical University, Red Star Hospital of the 13th Division of Xinjiang Production and Construction Corps and Chengdu Women's and Children's Central Hospital between August 2016 and September 2022. Patients were divided into a Good Response (GR) group and a Poor Response (PR) group based on minimal residual disease (MRD) levels post-relapse treatment. The demographic data, blood and cytokine profiles, cytogenetic/molecular alterations, and therapeutic interventions were analyzed. Factors influencing response were screened using univariate and multivariate logistic regression models.</p><p><strong>Results: </strong>The GR group showed significantly higher white blood cell (WBC) counts (8.24 ± 2.21 × 10³/µL) compared to the PR group (7.50 ± 1.88 × 10³/µL; P = 0.004). Elevated levels of tumor necrosis factor-alpha (TNF-α) (22.78 ± 4.31 vs. 20.94 ± 4.28 pg/mL; <i>P</i> < 0.001) and interleukin-6 (IL-6) (112.48 ± 21.09 vs. 106.31 ± 20.77 pg/mL; <i>P</i> = 0.020) were linked to poor outcome. Hypodiploidy and combined genetic alterations in Ikaros family zinc finger 1 (IKZF1), nuclear receptor subfamily 3 group C member 1 (NR3C1), and B-cell translocation gene 1 (BTG1) were associated with poor response (<i>P</i> = 0.032 and <i>P</i> = 0.003, respectively). Blinatumomab usage was associated with improved outcome (<i>P</i> = 0.030). Multivariate analysis revealed that higher TNF-α and IL-6 levels were independent risk factors of PR, while higher WBC count was a protective factor.</p><p><strong>Conclusion: </strong>Chemotherapy efficacy in relapsed pediatric B-ALL is influenced by hematologic, cytokine, and genetic factors.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"897-912"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TIGAR alleviates cognitive impairment in rats with chronic cerebral hypoperfusion by suppressing oxidative stress and pyroptosis.","authors":"Jie Xiao, Min Wu, Hailong Li, Shufan Zhang, Jing Deng, Bihua Wu","doi":"10.62347/NWQS1671","DOIUrl":"https://doi.org/10.62347/NWQS1671","url":null,"abstract":"<p><strong>Background: </strong>It is postulated that oxidative stress and pyroptosis, which are induced by chronic cerebral hypoperfusion (CCH), contribute to the pathogenesis of vascular cognitive impairment (VCI). The protective role of TIGAR in neurologic illnesses has been the subject of extensive examination, yet its role in models of CCH-induced cognitive impairment remains unexplored. The objective of this study was to ascertain whether TIGAR is a neuroprotective agent in rats with CCH that reduces oxidative stress and pyroptosis.</p><p><strong>Methods: </strong>A CCH model was established in rats through the use of bilateral common carotid artery occlusion (BCCAO). The effects of TIGAR on cognitive function and anxiety-depressive behaviors in rats with CCH were examined. To this end, the Y-maze and open field tests were employed. Nissl and hematoxylin-eosin (H&E) staining were used to assess histologic changes in the CA1 area of the hippocampus. Hippocampal glutathione (GSH) activity, malondialdehyde (MDA) content, and NADPH/NADP+ ratio were measured using the WST-8 colorimetric method to assess oxidative stress. The expression of TIGAR and pyroptosis-related proteins was assessed by western blotting.</p><p><strong>Results: </strong>A model of CCH-induced cognitive impairment was successfully established. Four weeks after BCCAO, cerebral blood flow returned to normal in the rats, and cognitive impairment and anxiety-depression-like behavior developed. In rats with CCH, MDA levels increased, GSH activity and NADPH/NADP+ ratio decreased, and pyroptosis-related protein expression increased. The pathologic findings indicated that there was an exacerbation of neuronal injury in the CA1 area of the hippocampus and that the cells were loosely arranged. In rats with CCH, overexpression of TIGAR reduced pyroptosis-associated protein expression while increasing MDA content, GSH activity, and NADPH/NADP+ ratio. It promoted neuronal cell survival, and improved cognitive function and anxiety-depression-like behavior.</p><p><strong>Conclusion: </strong>Overexpression of TIGAR reduced CCH-induced oxidative stress and pyroptosis and ameliorated cognitive dysfunction and anxiety-depression-like behavior in rats. These findings suggest that TIGAR counteracts oxidative stress and prevents pyroptosis, making it a promising target for the treatment of VCI.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1223-1236"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined ureteroscopy and percutaneous nephroscopy in the oblique supine position successfully treated a ureteral double J stent misaligned to the inferior vena cava.","authors":"Wen-Zhen Ai, Hong-Bing Wei, Jun Zhou, Qi Lei","doi":"10.62347/SWQO7641","DOIUrl":"https://doi.org/10.62347/SWQO7641","url":null,"abstract":"<p><p>The intravascular migration of double J stent (DJS) represents an uncommon complication in urological surgery, necessitating prompt intervention to prevent a severe outcome. This report details an infrequent instance of double J stent transposition into the inferior vena cava (IVC) that was effectively addressed using a combined approach of ureteroscopy (URS) and percutaneous nephroscopy (PCNL) performed in the oblique supine position (OSP), without significant complications.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1162-1169"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors influencing disease-free survival after radical endometrial cancer surgery: an analysis of the competitive risk prediction mode.","authors":"Xing Cao, Jianhui Fang, Yanling Wei, Shanbin Liang","doi":"10.62347/BRVI1759","DOIUrl":"https://doi.org/10.62347/BRVI1759","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the factors influencing disease-free survival (DFS) of patients with endometrial cancer after surgery and construct a competing risk prediction model.</p><p><strong>Methods: </strong>Clinical data of endometrial cancer patients admitted to the First People's Hospital of Qinzhou City from October 2015 to January 2021 were retrospectively analyzed. A total of 280 patients were included, randomly split into a training set (202 cases) and a validation set (78 cases) in a 7:3 ratio using RStudio software. A Fine-Gray competing risk model was applied to the training set to identify factors associated with reduced postoperative DFS. Based on these factors, a prognostic prediction model was established, and a nomogram was created. The model's performance was evaluated using the concordance index (C-index), receiver operating characteristic (ROC) curve and calibration curve.</p><p><strong>Results: </strong>Multifactorial analysis revealed that age, body mass index (BMI), diabetes mellitus, depth of basal infiltration, cancer antigen 125 (CA125), and human epididymis protein 4 (HE4) were the factors influencing postoperative DFS in endometrial cancer patients (P < 0.05). In the training set, the constructed model showed AUC values of 0.773, 0.802, and 0.858 in predicting 1-, 2-, and 4-year DFS, respectively. In the validation set, the AUC values were 0.923, 0.829, and 0.746, respectively. The C-index in the training set and the validation set was 0.786 and 0.515, respectively. The calibration curve indicated that the predicted cumulative survival probabilities closely matched the actual probabilities in both the training and validation sets.</p><p><strong>Conclusions: </strong>The Fine-Gray competing risk prediction model is effective in identifying factors influencing postoperative DFS in patients with endometrial cancer. The nomograms derived from this model have a strong predictive value and can help clinicians in identifying high-risk patients and tailoring individualized interventions.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1265-1276"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Goal-directed fluid therapy improves volume loading and stabilizes hemodynamics in patients undergoing coronary artery bypass grafting.","authors":"Jibo Zhao, Yuanli Li, Tong Jia, Tengchen Feng, Hui Liu, Yan Gao, Jinliang Teng","doi":"10.62347/IUZM6291","DOIUrl":"https://doi.org/10.62347/IUZM6291","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To investigate the effects of goal-directed fluid therapy (GDFT) on volume load and hemodynamics in patients undergoing coronary artery bypass grafting (CABG).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective study analyzed data from 131 patients with coronary heart disease who underwent CABG between April 2020 and April 2023. Seventy-five patients who received GDFT were categorized as the observation group, while 56 patients who received routine liquid therapy served as the control group. Fluid intake and outflow, volume load, regional cerebral oxygen saturation (rSO&lt;sub&gt;2&lt;/sub&gt;), central venous blood oxygen saturation (ScvO&lt;sub&gt;2&lt;/sub&gt;), hemodynamic parameters, and blood lactic acid levels were measured at several time points: 30 min preoperatively (T0), 15 min after anesthesia induction (T1), 1 h intraoperatively (T2), 2 h intraoperatively (T3), and at the end of the operation (T4). Postoperative recovery and complication rates were also compared between the two groups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;There were no significant group differences in total fluid input, red blood cell infusion rate, autologous blood transfusion rate, and bleeding amount between the two groups (all &lt;i&gt;P&gt;0.05&lt;/i&gt;). However, the amount of Ringer's solution, and fluid intake/output were significantly lower compared to the control group (all &lt;i&gt;P&lt;0.05&lt;/i&gt;). Conversely, the observation group had higher hydroxyethyl starch input and greater urine output than the control group (&lt;i&gt;P&lt;0.05&lt;/i&gt;). The cardiac output (CO) in the observation group was remarkably higher than that in the control group at T2-T4 (&lt;i&gt;P&lt;0.05&lt;/i&gt;), while stroke volume variation (SVV) was lower in the observation group (&lt;i&gt;P&lt;0.05&lt;/i&gt;). The rSO&lt;sub&gt;2&lt;/sub&gt; and ScvO&lt;sub&gt;2&lt;/sub&gt; in the observation group were notably higher at T2 to T4 than those in the control group (&lt;i&gt;P&lt;0.05&lt;/i&gt;). There was no significant difference in mean arterial pressure (MAP) and heart rate (HR) between the two groups at each time point (&lt;i&gt;P&gt;0.05&lt;/i&gt;). The cardiac index (CI) was higher while the central venous pressure (CVP) was lower in the observation group at T2-T4 than those in the control group (both &lt;i&gt;P&lt;0.05&lt;/i&gt;). Blood lactate levels were significantly lower in the observation group at T2 to T4 (&lt;i&gt;P&lt;0.05&lt;/i&gt;). The duration of postoperative assisted ventilation, positive inotropic medication, ICU stay, and the overall hospital stay of the observation group were shorter than those in the control group (&lt;i&gt;P&lt;0.05&lt;/i&gt;), and the incidence of postoperative complications was significantly lower than that in the control group (&lt;i&gt;P&lt;0.05&lt;/i&gt;).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;GDFT improves cardiac function and reduces cardiac volume load in patients undergoing CABG. It helps stabilize intraoperative hemodynamics, reduces blood lactate levels, enhances oxygen supply to brain tissue (as reflected by improved rSO&lt;sub&gt;2&lt;/sub&gt; and ScvO&lt;sub&gt;2&lt;/sub&gt;), and accelerates postoperative recovery. Additionally","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1135-1143"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}